Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies.
Quote | Aptose Biosciences Inc. (NASDAQ:APTO)
Last: | $0.567 |
---|---|
Change Percent: | -3.87% |
Open: | $0.59 |
Close: | $0.567 |
High: | $0.59 |
Low: | $0.551 |
Volume: | 39,130 |
Last Trade Date Time: | 07/29/2024 03:00:00 am |
News | Aptose Biosciences Inc. (NASDAQ:APTO)
2024-07-19 17:23:30 ET More on Aptose Biosciences Seeking Alpha’s Quant Rating on Aptose Biosciences Historical earnings data for Aptose Biosciences Financial information for Aptose Biosciences Read the full article on Seeking Alpha For further...
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
Message Board Posts | Aptose Biosciences Inc. (NASDAQ:APTO)
Subject | By | Source | When |
---|---|---|---|
A nice short read on a PROTAC approach | dcaf7 | investorshub | 05/01/2023 12:22:38 AM |
Its not about revenue. | Tartiaboy | investorshub | 04/27/2023 7:20:11 PM |
The stock has dropped from the .60 area | Zeppo | investorshub | 04/25/2023 2:14:15 PM |
AML news. | dcaf7 | investorshub | 04/21/2023 5:09:01 PM |
TP53 rules. | Tartiaboy | investorshub | 04/20/2023 12:34:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...